Serial #76075378
DEAD

Serial Number

76075378

Owner

MERISTEM THERAPEUTICS

Attorney

Michael A Cantor

Filing Date

Jun 16, 2000

Add to watchlist:

No watchlists yet
View on USPTO

Serial #76075378 Trademark

Serial Number: 76075378 • Registration: 2623068

Serial #76075378 is a trademark filed by MERISTEM THERAPEUTICS on June 16, 2000. The trademark is classified under Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

MERISTEM THERAPEUTICS (6 trademarks)

8 RUE DES FRERES LUMIERE
F-6300 CLERMONT-FERRAND , FR

Entity Type: 03

Trademark Details

Filing Date

June 16, 2000

Registration Date

September 24, 2002

Published for Opposition

July 2, 2002

Cancellation Date

May 16, 2009

Goods & Services

Pharmaceutical preparations for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies; veterinary preparations for the treatment of rabies, obesity, auto-immune diseases, namely, feline immunodeficiency virus and simian immunodeficiency virus, in livestock, domestic pets and wild animals, namely foxes and rodents; acaricides, algaecides, biopesticides, herbicides, insecticides, miticides, pesticides and weed killers for agricultural, domestic or commercial use; pharmaceutical preparations produced from plants or containing proteins produced from plants, for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies; therapeutic proteins, hormones, peptides and their complexes, derivatives and cofactors, namely, human serum albumin, lactoferrin, hemoglobin, collagen and procollagen for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies; vaccines including antibodies or glycoproteins, namely, glycoprotein G, lipases, namely, gastric lipase, pancreatic lipase; and medicines and pharmaceutical preparations obtained from genetically modified plants or containing the extracts of genetically modified plants for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies

Proteins for use as ingredients in skin lotions, oils and creams; for use as ingredients in sun tan lotions, oils and creams; for use as ingredients in skin hydrating lotions, oils and creams, namely, collagen, serum albumin, RNA, DNA and their extracts, amino acids, ribosomes, ceramides, immunostimulating or in imunoregulatory hormones, all obtained from plants; and enzymes for use as ingredients in skin lotions, oils and creams; for use as ingredients in sun tan lotions, oils and creams; for use as ingredients in skin hydrating lotions, oils and creams, namely, proteases, hydrolases, lipases, deshydroxylases and cellulases, all obtained from plants

Chemicals for use in the manufacture of photographic materials, namely, paints, wetting agents, fixing agents, developing agents, and stabilizers; chemicals for use in the manufacture of paints, dyes, colorings, cosmetics, glues, and surfactants; chemicals for use in the manufacture of horticultural materials, namely, soil preparation agents and fertilizers; chemicals for use in the manufacture of hormones, peptides, enzymes, proteins in the nature of growth hormones for plants, animals and microbes and growth inhibitors and regulators; chemicals for use in the manufacture of diagnostic reagents, cell culture media, cell regulatory agents, amino acids, DNA fragments, RNA fragments, DNA probes, RNA probes, genetic cloning materials, and genetic expression amplifiers

Biological and biotechnological laboratory research services, namely genetic modification of plants and plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings, biological and biochemical analysis of genetically modified plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings; laboratory research in the field of in-vitro reproduction and regeneration of genetically modified plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings; biological laboratory services in the field of in-vitro reproduction and regeneration of genetically modified plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings; laboratory research in the area of field and greenhouse reproduction of genetically modified plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings; biological laboratory services in the area of field and greenhouse reproduction of genetically modified plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings; laboratory research and tests regarding genetically modified plants; laboratory research featuring the expression of therapeutic, cosmetic or nutritional proteins or protein fragments through genetic modification, regeneration, and reproduction of plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings

Filing History

CANCELLED SEC. 8 (6-YR)
May 16, 2009 C8..
REVIEW OF CORRESPONDENCE COMPLETE
Feb 18, 2009 CORV
PAPER RECEIVED
Feb 2, 2009 MAIL
CASE FILE IN TICRS
Dec 11, 2007 CFIT
REGISTERED-PRINCIPAL REGISTER
Sep 24, 2002 R.PR
PUBLISHED FOR OPPOSITION
Jul 2, 2002 PUBO
NOTICE OF PUBLICATION
Jun 12, 2002 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 30, 2002 CNSA
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 5, 2001 CRFA
FINAL REFUSAL MAILED
Jul 5, 2001 CNFR
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 23, 2001 CRFA
Sec. 1(B) CLAIM DELETED
Feb 23, 2001 1.BD
NON-FINAL ACTION MAILED
Dec 18, 2000 CNRT
ASSIGNED TO EXAMINER
Nov 17, 2000 DOCK